Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Phase 3

Completed

Conditions: Lymphoma, Follicular

Interventions: Biological: CT-P10
Biological: Rituxan
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2014-06-13

Last Posted Date: 2020-01-29

Lead Sponsor: Celltrion

Target Recruit Count: 140

Registration Number: NCT02162771

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

Phase 2

Withdrawn

Conditions: Prostate Cancer
Localized Prostate Cancer

First Posted Date: 2014-06-10

Last Posted Date: 2015-01-26

Lead Sponsor: Kenneth Pienta, MD

Registration Number: NCT02159690

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Pneumocystis Jerovici Pneumonia in Infants and Steroids

Not Applicable

Completed

Conditions: Pneumonia, Pneumocystis Jerovici

Interventions: Drug: Prednisone
Drug: Placebo

First Posted Date: 2014-05-29

Last Posted Date: 2015-12-11

Lead Sponsor: Kamuzu University of Health Sciences

Target Recruit Count: 78

Registration Number: NCT02149433

Locations: 🇲🇼
Queen Elizabeth Central Hospital, Blantyre, Malawi

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Dasatinib
Procedure: Lumbar Puncture
Procedure: Magnetic Resonance Imaging
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Methotrexate Sodium
Drug: Prednisone
Drug: Vincristine
Drug: Vincristine Sulfate
Procedure: X-Ray Imaging

First Posted Date: 2014-05-21

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT02143414

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States

and more 194 locations

Prednisone for Heart Failure Patients With Hyperuricemia

Phase 2

Completed

Conditions: Heart Failure, Hyperuricemia

Interventions: Drug: Prednisone
Drug: Allopurinol

First Posted Date: 2014-05-02

Last Posted Date: 2018-10-16

Lead Sponsor: Hebei Medical University

Target Recruit Count: 205

Registration Number: NCT02129764

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

Interventions: Drug: Abiraterone Acetate
Drug: Prednisone
Drug: JNJ-56021927

First Posted Date: 2014-04-28

Last Posted Date: 2025-01-09

Lead Sponsor: Aragon Pharmaceuticals, Inc.

Target Recruit Count: 57

Registration Number: NCT02123758

Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Phase 4

Withdrawn

Conditions: Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2014-04-21

Last Posted Date: 2019-08-28

Lead Sponsor: Loma Linda University

Registration Number: NCT02119273

Locations: 🇺🇸
Loma Linda Sinus and Allergy Center, Redlands, California, United States

Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis

Phase 2

Conditions: Alcoholic Hepatitis

Interventions: Drug: Prednisone
Drug: Rifaximin

First Posted Date: 2014-04-17

Last Posted Date: 2016-11-04

Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute

Target Recruit Count: 29

Registration Number: NCT02116556

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain

and more 1 locations

A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Phase 4

Completed

Conditions: Wegener's Granulomatosis or Microscopic Polyangiitis

Interventions: Drug: Methylprednisolone
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2014-04-16

Last Posted Date: 2022-07-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT02115997

Locations: 🇮🇳
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India
🇮🇳
St. John's Medical College Hospital; Rheumatology, Bangalore, India
🇮🇳
Medanta-The Medicity, Gurgaon, Haryana, India

and more 7 locations

A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis

Phase 3

Terminated

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide, Maintenance Phase
Drug: Cyclophosphamide, Induction Phase
Drug: Prednisone

First Posted Date: 2014-03-07

Last Posted Date: 2014-07-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT02081183

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy